TSX:BLCO - Post Discussion
Post by
Betteryear2 on Jun 30, 2023 8:51am
Bausch + Lomb Will Acquire XIIDRA®
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced it has entered into a definitive agreement with Novartis under which Bausch + Lomb will acquire XIIDRA® (lifitegrast ophthalmic solution) 5%, a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease (DED) focusing on inflammation associated with dry eye.
Bausch + Lomb Will Acquire XIIDRA® | Business Wire
Be the first to comment on this post